A Prospective 1-Year Follow-Up of Glycemic Status and C-Peptide Levels of COVID-19 Survivors with Dysglycemia in Acute COVID-19 Infection

David Tak Wai Lui,Chi Ho Lee,Ying Wong,Carol Ho Yi Fong,Kimberly Hang Tsoi,Yu Cho Woo,Kathryn Choon Beng Tan
DOI: https://doi.org/10.4093/dmj.2023.0175
2024-03-14
Diabetes & Metabolism Journal
Abstract:Download PDF Background We evaluated changes in glycemic status, over 1 year, of coronavirus disease 2019 (COVID-19) survivors with dysglycemia in acute COVID-19. Methods COVID-19 survivors who had dysglycemia (defined by glycosylated hemoglobin [HbA1c] 5.7% to 6.4% or random glucose ≥10.0 mmol/L) in acute COVID-19 were recruited from a major COVID-19 treatment center from September to October 2020. Matched non-COVID controls were recruited from community. The 75-g oral glucose tolerance test (OGTT) were performed at baseline (6 weeks after acute COVID-19) and 1 year after acute COVID-19, with HbA1c, insulin and C-peptide measurements. Progression in glycemic status was defined by progression from normoglycemia to prediabetes/diabetes, or prediabetes to diabetes. Results Fifty-two COVID-19 survivors were recruited. Compared with non-COVID controls, they had higher C-peptide ( P < 0.001) and trend towards higher homeostasis model assessment of insulin resistance ( P =0.065). Forty-three COVID-19 survivors attended 1-year reassessment. HbA1c increased from 5.5%±0.3% to 5.7%±0.2% ( P <0.001), with increases in glucose on OGTT at fasting ( P =0.089), 30-minute ( P =0.126), 1-hour ( P =0.014), and 2-hour ( P =0.165). At baseline, 19 subjects had normoglycemia, 23 had prediabetes, and one had diabetes. Over 1 year, 10 subjects (23.8%; of 42 non-diabetes subjects at baseline) had progression in glycemic status. C-peptide levels remained unchanged ( P =0.835). Matsuda index decreased ( P =0.007) and there was a trend of body mass index increase from 24.4±2.7 kg/m 2 to 25.6±5.2 ( P =0.083). Subjects with progression in glycemic status had more severe COVID-19 illness than non-progressors ( P =0.030). Reassessment was not performed in the control group. Conclusion Subjects who had dysglycemia in acute COVID-19 were characterized by insulin resistance. Over 1 year, a quarter had progression in glycemic status, especially those with more severe COVID-19. Importantly, there was no significant deterioration in insulin secretory capacity.
endocrinology & metabolism
What problem does this paper attempt to address?